OraSure Technologies Up Following FDA Approval for New Product
June 25, 2010 · Filed Under Uncategorized
OraSure Technologies, Inc. (NASDAQ: OSUR) was up this morning $0.41 (8.45%) to $5.26 following FDA approval for its OraQuick® Hepatitis C (“HCV”) Rapid Antibody Test, making the test the first rapid HCV test approved for sale in the U.S.
OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices, including tests for the detection of antibodies for the HIV virus and, now, rapid HCV tests.
Comments
Leave a Reply
